论文部分内容阅读
目的观察IEA方案治疗难治性急性淋巴细胞白血病的疗效和不良反应。方法 15例难治性急性淋巴细胞白血病患者均给予IEA方案(IDA10mg/d,第1～3天,第15～17天;足叶乙苷(VP16)0.1g/d,第1-5天;阿糖胞苷Ara-C0.2g/d,第1～7天。结果 13例患者中,第1疗程获CR8例,CR率61.3%,PR1例,总有效率69.2%;NR4例。结论 IEA方案治疗难治性急性淋巴细胞白血病的疗效好,不良反应轻。
Objective To observe the efficacy and adverse reactions of IEA regimen in the treatment of refractory acute lymphoblastic leukemia. Methods Fifteen patients with refractory acute lymphoblastic leukemia were treated with IEA (IDA 10 mg / d, days 1 to 3, days 15 to 17; VP16 0.1g / d for days 1-5) Cytarabine Ara-C0.2g / d on days 1 to 7. Results Of the 13 patients, the first course of treatment was CR8, the CR rate was 61.3%, PR1 cases, the total effective rate 69.2%; NR4 cases.Conclusion IEA Program treatment of refractory acute lymphoblastic leukemia with good efficacy, mild adverse reactions.